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The activation of type I (y). II (j) and III (a) protein kinase C (PKC) subspecies by phosphatidylserine (PS) and diacylglycerol (DAG) is inhibited 
by micromolar concentrations of triphenylacrylonitrile (TPE) antiestrogens. TPE A (with p-hydroxy and p-diethylaminoethoxy groups on the 3- 
and 3’-phenyl rings, respectively) interacts with PS-vesicles as well as with the regulatory domain of PKC. probably at a site different from the 
Ca2’ and DAG binding sites. The interaction of TPE A with the regulatory domain of enzyme is very slow. Apparently. TPE A does not interact 
with the catalytic domain of PKC. In contrast, dnother TPE derivative, TPE B (with a p-hydroxy group on each of the three phenyl rings) inhibits 
the enzyme activity in a competitive manner with respect to ATP. suggesting that this TPE interacts with the catalytically active site of the enzyme. 
It seems likely that various TPE antiestrogen derivatives may exert their inhibitory action on PKC by multiple different mechanisms. 
Protein kinase C: Antiestrogen; Triphenylethylene; Human breast cancer 
1. INTRODUCTION 
Triphenylethylenes (TPE derivatives), a well-known 
chemical family (for a review, see [I]), bind to estrogen 
receptor (ER) and exhibit either estrogenic, an- 
tiestrogenic and/or antitumoral activities [l-3]. In 
spite of the widespread use of TPE tamoxifen for treat- 
ment of hormone-dependent breast cancer, its 
mechanism of action remains to be elucidated. Phar- 
macological studies of several members of a related 
chemical family, triphenylacrylonitriles, have shown 
that their ability to inhibit human breast cancer cell 
proliferation depends largely on the structure and posi- 
tion of substituents on the triphenyl skeleton [4-71. 
Since it is generally accepted that interaction of TPEs 
with ER is not the sole basis of their antiproliferative 
effect on human breast cancer cells [7-lo], additional 
mechanisms appear to be involved in the observed 
antitumoral action (for a review, see [ 111). 
It has been proposed that an important target of 
TPEs is protein kinase C (PKC) [12] which plays a 
critical role in growth regulation (for reviews, see 
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[13,14]). To understand better the mechanism of inhibi- 
tion of PKC by TPEs, we have examined the kinetics 
of the inhibitory actions of two triphenylacrylonitrile 
derivatives which represent different chemical 
subclasses (Fig. 1) (A and B correspond to TPEs I and 
3 in a previous report [IS].) TPE A (with one phenolic 
and one basic residue) profoundly inhibits, in the 
nanomolar concentration range, estrogen-induced pro- 
liferation of MCF-7 cells, an ER-positive cell line deriv- 
ed from human breast cancer metastasis, and this 
inhibition is overcome by estrogen [7]. TPE B (with 
three phenolic residues) exerts only partial inhibition on 
this cell line [6,7]. Both TPEs at the micromolar con- 
centration range, inhibit ER-positive as well as ER- 
negative breast cancer cell lines, and this inhibition is 
not overcome by estrogen (estrogen irreversible effect) 
171. 
Our earlier study [ 15) has suggested that TPEs inhibit 
PKC by more than a single mechanism. Further 
evidence for interaction of these TPEs with PS-vesicles 
and with the regulatory and catalytic domains of PKC 
will be presented herein. 
2. MATERIALS AND METHODS 
2. I. Chemicals and materials 
The preparation of TPEs and their analytical characteristics have 
been described previously [5,7]. The isomeric purity was checked 
before use by HPLC analysis as described [7]. 
2.2. Enzyme purification 
PKC was purified from the rat brain soluble fraction and separated 
into three types, type I, II and 111, as described [16]. 
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TPE A TPE B 
Fig. 1. Structures of TPE derivatives, 
2.3. Assay of PKC 
Unless otherwise indicated, the standard reaction mixture 
(0.125 ml) contained buffer A (20 mM Tris-HCI at pH 7.5), 10 pM 
[y-3ZP]ATP (400-500 cpm/pmol), 5 mM magnesium acetate, 
0.01 mM EGTA and 0.01 mM EDTA (these EGTA and EDTA were 
from the enzyme fraction), 200pgIml calf thymus Hl histone, 
0.1 mM CaCl2, 8 pg/ml phosphatidylserine (PS) vesicles, 0.8 pg/ml 
DO, PKC and, where indicated, TPE. TPEs were dissolved in 
DMSO. PS and diolein (DO) were stored in chloroform solution. The 
PS solution was evaporated under a stream of nitrogen (when DO 
was used, it was mixed first with PS in chloroform). The residue was 
resuspended in ice-cold buffer A, vigorously mixed using a vortex 
mixer for 1 min, and sonicated with a tip sonicator for 1 min at 0°C. 
TPE solutions in DMSO were diluted in buffer A and, when in- 
dicated, vigorously mixed (vortex) for I .5 min with an aliquot of the 
sonicated PS-vesicles (the final DMSO concentration in the incuba- 
tion was 5% (v/v)). The PS-TPE solution was added to the reaction 
mixture, and the phosphorylation reaction was started by the addi- 
tion of PKC (approx. 0.05 pg). The incubation was carried out for 
3 min at 30°C under gentle shaking (40 cycles per min). The radioac- 
tivity of acid-precipitable materials was determined by liquid scin- 
tillation. All experiments were carried out at least twice. 
2.4. Assay of Cd’- and PS-independent activity of PKC 
With protamine sulfate as phosphate acceptor, PKC exhibits full 
enzymatic activity in the absence of PS, DAG and Ca*’ [17]. This 
protein kinase activity was determined with 400pg/ml protamine 
sulfate in the presence of EGTA (0.5 mM in final concentration) in- 
stead of Ca’+, PS and DO. TPE was added directly to the reaction 
mixture (the final DMSO concentration in the incubation mixture 
was 5% (v/v)). 
2.5. Preincubation experiments of TPEs with PKC 
The preincubation mixture in ice-cold buffer A (0.105 ml) contain- 
ed 0.01 mM EGTA, 0.01 mM EDTA, 0.7% glycerol (v/v), 
29.8 pg/ml bovine serum albumin (that stabilizes PKC without affect 
on TPE action), TPE or DMSO (5.9% (v/v)) with or without 
0.5 fig/ml PS. TPE was added directly (TPE and PS-vesicles were not 
mixed vigorously) to this mixture (the final DMSO concentration in 
the preincubation mixture was 5.9% (v/v)). The preincubation was 
started by the addition of PKC (approx. 0.3 pup) and carried out at 
0°C for various periods of time. The phosphorylation reaction was 
then initiated by the addition of other cofactors and substrate, and 
the incubation was carried out for 2 min at 30°C as described above 
(the final volume was 0.125 ml). 
3. RESULTS 
3.1. Inhibition of PKC by TPEs 
In the presence of Ca2+ and PS (plus or minus 
DAG), type I, II and III PKC subspecies were all in- 
hibited by TPEs A and B in a concentration-dependent 
manner. TPE A inhibited PKC with an I& of 
l--5 PM, whereas TPE B inhibited the enzyme at 
20-fold higher concentrations. Kinetic analysis in- 
dicated that the TPEs interact with PS-vesicles and/or 
PKC but not with Ca2+ and DAG (see below). This in- 
hibition was not competitive with respect to Ca2+ nor 
to DAG. Since essentially similar results were obtained 
for type I, II and III PKC, only the results obtained for 
type III PKC, which is commonly present in mam- 
malian tissues and cell types including human breast 
cancer cells (PKC III (a) is one of the PKC subspecies 
expressed in human breast cancer cells (Eric Bignon et 
al., manuscript in preparation)), will be given below. 
3.2. Interaction with phospholipid 
PS-vesicles and TPE solutions, prepared separately 
as specified in section 2, were vigorously mixed using a 
vortex mixer for various periods of time. This solution 
was then added to the reaction mixture containing 
Ca2+, Mg2+, ATP and Hl histone in buffer A. The 
phosphorylation reaction was started by the addition of 
PKC and carried out for 3 min. It was found that TPE 
A markedly inhibited the reaction only after being 
vigorously mixed with PS-vesicles for a certain period 
of time (Fig. 2). It is unlikely that this profound in- 
hibitory action of TPE A was simply due to its direct 
interaction with the PKC molecule or with other com- 
ponents in the reaction mixture, because TPE A show- 
ed practically no effect unless it was vigorously mixed 
with PS-vesicles. The presence of higher concentrations 
of PS during its mixing with TPE A fully overcame this 
inhibitory action according to a sigmoidal PS dose 
response curve, which may reflect PS-TPE interaction 
(Fig. 3). Other procedures such as sonication of the 
I 
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Fig. 2. PKC III activity as a function of mixing time (vortex) of PS- 
vesicles with TPEs. PS-vesicles and TPE solutions were prepared 
separately as specified in section 2, and mixed vigorously using a 
vortex mixer for various periods of time. Then, this solution was 
added to the reaction mixture containing Ca*+, Mg*+, ATP, HI 
histone in buffer A. When TPE was mixed with vehicles, PS-vesicles 
were added during the phosphorylation reactions. The 
phosphorylation reaction was started by the addition of PKC, and 
carried out for 3 min. (A) 60+M TPE A, (0) 1OOpM TPE B, (m) 
vehicle alone. The results are normalized to the maximum activity 
that was obtained in the presence of Ca’+ and lipids. 
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TPE-PS solution, which facilitate the interaction of 
TPE with phospholipid, also resulted in profound in- 
hibition of the reaction (data not shown). The results 
suggest that TPE A interacts with the phospholipid- 
vesicles and thereby inhibits PKC activation. 
In contrast, the inhibitory action of TPE B did not 
depend on its premixing with PS-vesicles or on the PS 
concentration (Figs 2 and 3). A possible mechanism of 
this inhibition is described below. 
3.3. Interaction with regulatory domain of PKC 
In the next set of experiments, TPE and PKC were 
preincubated first (in the absence of PS) at 0°C for 
various periods of time. PKC activity was then deter- 
mined in a 2 min incubation assay. The reaction was 
started by the addition of this enzyme-TPE solution to 
the incubation mixture containing Ca’+, Mg2+, PS, 
ATP and Hl histone as a phosphate acceptor in buffer 
A. As shown in Fig. 4A, without preincubation (time 
0), TPE A showed no effect on enzyme activity, sug- 
gesting that this compound does not significantly in- 
teract with PS-vesicles nor with other components 
during the 2 min PKC assay. When the preincubation 
was prolonged, however, the enzyme activity decreas- 
ed, and after 40 min preincubation, the enzyme showed 
practically no activity. Although the kinetics of this in- 
hibition was very slow, it is unlikely that TPE A 
denatured PKC irreversibly, because, when the 
substrate, HI histone, was replaced by protamine 
sulfate, which does not require Ca’+, PS and DAG for 
enzymatic reaction [17], the enzyme was almost fully 
active under the prolonged preincubation (Fig. 4B). 
PS Concentration (@ml) 
Fig. 3. PKC III activity as a function of PS concentration in the 
presence of TPEs. PS-vesicles and TPE solutions were prepared 
separately as specified in section 2, and mixed vigorously using a 
vortex mixer for 1.5 min. Then, this solution was added to the 
reaction mixture containing Ca*+, Mg”, ATP, HI histone in buffer 
A. When TPE was mixed with vehicles, PS-vesicles were added 
during the phosphorylation reactions. The phosphorylation reaction 
was started by the addition of PKC, and carried out for 3 min. (A) 
60 pM TPE A, (0) 100 pM TPE B, (m) vehicle alone. The results are 
normalized to the maximum activity that was obtained in the 
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Fig. 5. Effect of PS concentration on inhibition of PKC activation by 
TPEs. (A) Various amounts of PS-vesicles were added after 40 min 
preincubation of PKC with TPEs; (B) various amounts of PS-vesicles 
were added during 40 min preincubation of PKC with TPEs (TPEs 
and PS vesicles were not vigorously premixed). Other conditions were 
identical to those given in Fig. 3. (A) 60pM TPE A, (0) 100/M 
TPE B, (m) vehicle alone. The results are normalized to the maximum 
presence of Ca’+ and lipids. activity that was obtained in the presence of Ca’+ and lipids. 
56 
LETTERS October 1990 
01 I 
0 20 40 60 
Preincubation l‘ime (min.) 
Fig. 4. PKC III activity as a function of preincubation time of TPEs 
with enzyme. TPEs and PKC were preincubated (in the absence of PS 
vesicles) at 0°C for various periods of time under gentle shaking. The 
phosphorylation reaction was started by the addition to this solution 
of the reaction mixture containing (A) Ca”, Mg’+, PS, ATP and Hl 
histone in buffer A, or (B) ATP, Mg*+ and protamine sulfate in 
buffer A, under the conditions specified in section 2. The reaction 
was carried out for 2 min. (A) 60pM TPE A, (0) 100,~M TPE B, 
(m) vehicle alone. The results are normalized to the activity that was 
obtained in the presence of Ca“ and lipids (A), or 0.5 mM EGTA 
(B). 
Similarly, TPE A did not significantly inhibit PKM, a 
catalytically active fragment of PKC. The results in- 
dicate that TPE A may also interact slowly with the 
regulatory domain of PKC, thereby preventing subse- 
quent activation of the enzyme by Ca*+ and lipid cofac- 
tors. After 40 min preincubation, the activity of the 
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Fig. 6. PKC activity as a function of ATP concentration. PKC 
activity was determined as described in section 2 in the presence of 
(A) Ca’+, Mg”, PS, and Hl histone in buffer A, or (B) EGTA, 
Mg’+, and protamine sulfate in buffer A (double-reciprocal plot 
(Inset), l/PKC activity (l/V: nmol-‘-min) as a function of l/ATP 
concentration (JLM-I)). (m) Control, (0) 0.5 mM EGTA, (A) 60pM 
TPE A, (0) 100 PM TPE B. Similar results were obtained with types 
I and II PKC. The K, values of ATP for type I, II and III PKC were 
6.75 + 0.04, 6.74 i 0.59 and 6.67 k 0.04 PM with Hl histone, and 
10 f 3, 18 + 1 and 11 f 3 PM with protamine sulfate as a substrate, 
respectively. The results are normalized to the maximum activity that 
was obtained in the presence of Ca” and lipids (A) or 0.5 mM EGTA 
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enzyme could not be restored by the subsequent addi- 
tion of PS-vesicles (Fig. 5A). However, the presence of 
PS during the preincubation prevented the enzyme in- 
activation by TPE A (Fig. 5B). 
Unlike TPE A, TPE B inhibited phosphorylation of 
both Hl histone (Fig. 4A) and protamine sulfate 
(Fig. 4B) with or without preincubation with the en- 
zyme. This inhibition was not significantly affected by 
PS-vesicles under various conditions tested (Fig. 5). 
3.4. Interaction with catalytic domain of PKC 
The phosphorylation of protamine sulfate, which 
does not require Ca2+, PS and DAG, was apparently 
insensitive to TPE A, but significantly inhibited by 
TPE B (Fig. 4B). Similar results were obtained with a 
catalytically active fragment of PKC (PKM), sug- 
gesting that TPE B, but not TPE A, interacts directly 
with the catalytic domain of enzyme. Inhibition of 
PKC by TPE B was competitive with ATP with either 
Hl histone or protamine sulfate being used as a 
phosphate acceptor (Fig. 6A and B), whereas inhibition 
by TPE A was not reversed by increasing ATP concen- 
trations. The catalytic subunit of cyclic AMP- 
dependent protein kinase was insensitive to these TPEs 
under comparable conditions. 
4. DISCUSSION 
The present studies have shown that TPE A interacts 
with PS vesicles as well as with the regulatory domain 
of PKC, thereby inhibiting the enzyme activation as 
Protein Kinase C Protein Kinase M 
Fig. 7. Schematic representation of TPE interaction with PKC, PKM 
and PS-vesicles. The solid arrows represent possible main 
interactions between these components. The interaction of TPE A 
with PKC may induce a conformational change of the enzyme, but 
its binding site to the PKC molecule remains undefined. TPE B 
probably interacts with the ATP-binding site of PKC and PKM. 
schematically shown in Fig. 7. This interaction of TPE 
A with PS vesicles and PKC appears to proceed slowly. 
Although increasing the concentration of PS vesicles 
apparently overcomes the inhibitory component of 
TPE A in its interaction with PS vesicles, there is no in- 
dication that TPE A competes with PS vesicles for the 
same site of the regulatory domain of enzyme. It is 
possible that TPE A inhibits the association of enzyme 
with PS vesicles by altering the phospholipid lamellar 
structure, although the precise mechanism of PKC ac- 
tivation by phospholipid still remains largely unex- 
plored. On the other hand, the inhibitory component of 
TPE A in its interaction with PKC is an apparently ir- 
reversible process, which involves some conformational 
change of the enzyme molecule. The binding of TPE A 
to PKC appears to be prevented by prior association of 
the enzyme with PS vesicles. A conformational change 
of the PKC molecule by membrane phospholipid has 
been suggested by Bazzi and Nelsestuen [18] and 
Newton and Koshland, Jr. [19]. 
TPE B, like a certain diphenylethylene analogue [20], 
interacts with the catalytic domain of PKC. TPE A at 
higher concentrations (in the range of 100-600 PM) 
may also interact with the catalytic domain of enzyme, 
and inhibits its PS- and Ca2+-independent activity [21]. 
The inhibitory action of TPEs A and B on PKC 
described above apparently parallels their observed ER- 
independent action on human breast cancer cell pro- 
liferation [7]. Although the plasma tamoxifen level 
varies greatly depending on the patient and therapy 
conditions, the tissue concentration of this compound 
during the cancer treatment has been estimated to be 
sufficiently high to inhibit PKC 122,231. The antitumor 
action of TPEs may, therefore, probably result from 
several mechanisms, involving their interaction with 
ER and also with other molecular targets, such as PKC 
and Ca’+/calmodulin-dependent protein kinase [3] 
which may also play a role in growth regulation. 
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